272437-84-0

Basic information

• Product Name: 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid
• Synonyms: 2H-1,4-Benzothiazine-6-carboxylic acid, 3,4-dihydro-3-oxo-;3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid;3,4-Di hydro-3-oxo-2h-benzo[1,4]thiazin-6-carboxylic acid;3-keto-4H-1,4-benzothiazine-6-carboxylic acid;3-oxo-4H-1,4-benzothiazine-6-carboxylic acid;AN-829/25059005;BAS 13090967;CBDivE_002679
• CAS NO: 272437-84-0
• Molecular Formula: C₉H₇NO₃S
• Molecular Weight: 209.23
• Mol File: 272437-84-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 483.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.485±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.82±0.20(Predicted)
• CAS DataBase Reference: 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid(272437-84-0)
• EPA Substance Registry System: 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid(272437-84-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 272437-84-0(Hazardous Substances Data)

Usage

General Description

3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid is a chemical compound with a molecular formula C9H7NO3S. It is a heterocyclic compound containing a benzothiazine ring and a carboxylic acid functional group. 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid has been studied for its potential biological activities, including its potential as a drug candidate for various medical applications. Research has shown that it may have anti-inflammatory, anti-bacterial, and anti-cancer properties. Additionally, it has been investigated for its potential to inhibit certain enzymes and receptors in the body. 3,4-Dihydro-3-oxo-2H-benzo[b][1,4]thiazine-6-carboxylic acid is of interest to researchers in the pharmaceutical and medical fields for the development of new drugs and treatments.

Upstream product

• 204863-53-6 ethyl 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylate 
• 188614-01-9 methyl 3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxylate 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 204863-51-4 4-ethoxycarbonylmethylsulfanyl-3-nitrobenzoic acid 

Downstream Products

• 697306-29-9 N,N-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-carboxamide 
• 443955-31-5 6-hydroxymethyl-4H-benzo[1,4]thiazin-3-one 
• 1236221-12-7 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid {1-[2-(7-methoxy-quinoxalin-2-ylsulfanyl)-ethyl]-piperidin-4-yl}-methyl-amide 
• 1236221-13-8 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid {1-[2-(6-methoxy-quinolin-3-ylsulfanyl)-ethyl]-piperidin-4-yl}-amide 
• 1236220-60-2 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid {1-[2-(7-methoxy-quinoxalin-2-yloxy)-ethyl]-piperidin-4-yl}-amide 
• 1312576-60-5 3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid [1-(6-methoxy-3,4-dihydro-2H-1-oxa-9-aza-phenanthrene-3-yl)-piperidin-4-yl]-amide 
• 1392138-96-3 C₂₃H₂₄FN₃O₂S 
• 1392139-43-3 C₂₃H₂₄FN₃O₂S 
• 1392139-47-7 C₂₃H₂₄FN₃O₂S 
• 1392139-48-8 C₂₃H₂₄FN₃O₂S 
• 1392139-49-9 C₂₃H₂₃F₂N₃O₂S 
• 1392139-50-2 C₂₃H₂₃F₂N₃O₂S 
• 1392139-52-4 C₂₇H₂₇N₃O₂S 
• 1392138-95-2 C₂₃H₂₆FN₃O₂S 

Relevant articles and documents

Discovery of a Plasmodium falciparum Glucose-6-phosphate Dehydrogenase 6-phosphogluconolactonase Inhibitor (R,Z)-N-((1-Ethylpyrrolidin-2-yl)methyl)-2- (2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro

A high-throughput screen of the NIH's MLSMR collection of ～340000 compounds was undertaken to identify compounds that inhibit Plasmodium falciparum glucose-6-phosphate dehydrogenase (Pf G6PD). PfG6PD is important for proliferating and propagating P. falciparum and differs structurally and mechanistically from the human orthologue. The reaction catalyzed by glucose-6-phosphate dehydrogenase (G6PD) is the first, rate-limiting step in the pentose phosphate pathway (PPP), a key metabolic pathway sustaining anabolic needs in reductive equivalents and synthetic materials in fast-growing cells. In P. falciparum, the bifunctional enzyme glucose-6-phosphate dehydrogenase-6- phosphogluconolactonase (Pf GluPho) catalyzes the first two steps of the PPP. Because P. falciparum and infected host red blood cells rely on accelerated glucose flux, they depend on the G6PD activity of PfGluPho. The lead compound identified from this effort, (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2- fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carbox-amide, 11 (ML276), is a submicromolar inhibitor of PfG6PD (IC50 = 889 nM). It is completely selective for the enzyme's human isoform, displays micromolar potency (IC50 = 2.6 μM) against P. falciparum in culture, and has good drug-like properties, including high solubility and moderate microsomal stability. Studies testing the potential advantage of inhibiting Pf G6PD in vivo are in progress.

Bicyclic pyrazole compounds as antibacterial agents

Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.

AMINE COMPOUNDS

The present invention provide a compound of the formula:wherein ring A represents an aromatic ring optionally having substituents; B, Y and Ya are the same or different and each represents a bond, etc.; R1 and R2 are the same or different and each represents a hydrogen atom, etc.; R3 represents a hydrogen atom, etc.; R4 and R5 are the same or different and each represents a hydrogen, etc.; R6 represents an indolyl group optionally having substituents; and Z and Za are the same or different and each represents a hydrogen atom, etc.; or a salt thereof or a prodrug thereof, having a somatostatin receptor binding inhibition activity and is useful for preventing and/or treating diseases associated with somatostatin.